6-hydroxydopa has been researched along with levodopa in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Labruyere, J; Olney, JW; Price, MT; Stewart, GR; Wang, GJ; Zorumski, CF | 1 |
| Kannari, K; Matsunaga, M; Shen, H; Suda, T; Yamato, H | 1 |
| Borsini, F; Morelli, M; Pinna, A; Pontis, S | 1 |
| Agostinho, P; Aguiar, AS; Cunha, RA; Ferreira, SG; Prediger, RD; Silva, HB; Speck, AE; Tomé, ÂR | 1 |
5 other study(ies) available for 6-hydroxydopa and levodopa
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocycloheptenes; Dihydroxyphenylalanine; Dizocilpine Maleate; Hippocampus; Huntington Disease; Levodopa; Neurons; Parkinson Disease; Quinoxalines; Receptors, Neurotransmitter; Retina | 1990 |
Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Extracellular Space; Fluoxetine; Levodopa; Male; Parkinson Disease; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2001 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functional Laterality; Immunohistochemistry; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Triazoles; Tyrosine 3-Monooxygenase; Vibrissae | 2007 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dyskinesia, Drug-Induced; Exercise Therapy; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Mice, Inbred C57BL; Motor Activity; Neuronal Plasticity; Parkinsonian Disorders; Running; Time Factors | 2021 |